By cell surface biotinylation assay of the same hepatoma cell model, Johnson et al. reported that ezetimibe could inhibit cholesterol binding to NPC1L1 but not NPC1L1 internalization, and the endocytosis inhibitors (Dyngo-4a or Pitstop 2) blocked completely NPC1L1 endocytosis but not ezetimibe-sensitive cholesterol uptake. Here, NPC1L1 is linked to hepatocellular carcinoma.